BACKGROUND: The role of mitochondria in cancer is poorly understood. Ulcerative colitis (UC) is an inflammatory bowel disease that predisposes to colorectal cancer and is an excellent model to study tumor progression. Our goal was to characterize mitochondrial alterations in UC tumorigenesis. METHODS: Nondysplastic colon biopsies from UC patients with high-grade dysplasia or cancer (progressors; n = 9) and UC patients dysplasia free (nonprogressors; n = 9) were immunostained for cytochrome C oxidase (COX), a component of the electron transport chain, and were quantified by multispectral imaging. For six additional progressors, nondysplastic and dysplastic biopsies were stained for COX and additional mitochondrial proteins including PGC1α, the master regulator of mitochondrial biogenesis. Mitochondrial DNA (mtDNA) copy number was determined by quantitative polymerase chain reaction. Generalized estimating equations with two-sided tests were used to account for correlation of measurements within individuals. RESULTS: Nondysplastic biopsies of UC progressors showed statistically significant COX loss compared with UC nonprogressors by generalized estimating equation (-18.5 units, 95% confidence interval = -12.1 to -24.9; P < .001). COX intensity progressively decreased with proximity to dysplasia and was the lowest in adjacent to dysplasia and dysplastic epithelium. Surprisingly, COX intensity was statistically significantly increased in cancers. This bimodal pattern was observed for other mitochondrial proteins, including PGC1α, and was confirmed by mtDNA copy number. CONCLUSIONS: Mitochondrial loss precedes the development of dysplasia, and it could be used to detect and potentially predict cancer. Cancer cells restore mitochondria, suggesting that mitochondria are needed for further proliferation. This bimodal pattern might be driven by transcriptional regulation of mitochondrial biogenesis by PGC1α.
BACKGROUND: The role of mitochondria in cancer is poorly understood. Ulcerative colitis (UC) is an inflammatory bowel disease that predisposes to colorectal cancer and is an excellent model to study tumor progression. Our goal was to characterize mitochondrial alterations in UC tumorigenesis. METHODS:Nondysplastic colon biopsies from UC patients with high-grade dysplasia or cancer (progressors; n = 9) and UC patientsdysplasia free (nonprogressors; n = 9) were immunostained for cytochrome C oxidase (COX), a component of the electron transport chain, and were quantified by multispectral imaging. For six additional progressors, nondysplastic and dysplastic biopsies were stained for COX and additional mitochondrial proteins including PGC1α, the master regulator of mitochondrial biogenesis. Mitochondrial DNA (mtDNA) copy number was determined by quantitative polymerase chain reaction. Generalized estimating equations with two-sided tests were used to account for correlation of measurements within individuals. RESULTS: Nondysplastic biopsies of UC progressors showed statistically significant COX loss compared with UC nonprogressors by generalized estimating equation (-18.5 units, 95% confidence interval = -12.1 to -24.9; P < .001). COX intensity progressively decreased with proximity to dysplasia and was the lowest in adjacent to dysplasia and dysplastic epithelium. Surprisingly, COX intensity was statistically significantly increased in cancers. This bimodal pattern was observed for other mitochondrial proteins, including PGC1α, and was confirmed by mtDNA copy number. CONCLUSIONS: Mitochondrial loss precedes the development of dysplasia, and it could be used to detect and potentially predict cancer. Cancer cells restore mitochondria, suggesting that mitochondria are needed for further proliferation. This bimodal pattern might be driven by transcriptional regulation of mitochondrial biogenesis by PGC1α.
Authors: Karla G Sifroni; Carlos R Damiani; Cristhopher Stoffel; Mariane R Cardoso; Gabriela K Ferreira; Isabela C Jeremias; Gislaine T Rezin; Giselli Scaini; Patricia F Schuck; Felipe Dal-Pizzol; Emilio L Streck Journal: Mol Cell Biochem Date: 2010-05-04 Impact factor: 3.396
Authors: T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer Journal: Gastroenterology Date: 1994-08 Impact factor: 22.682
Authors: Damon May; Sheng Pan; David A Crispin; Keith Lai; Mary P Bronner; Jason Hogan; David M Hockenbery; Martin McIntosh; Teresa A Brentnall; Ru Chen Journal: J Proteome Res Date: 2010-10-20 Impact factor: 4.466
Authors: Jacintha N O'Sullivan; Jennifer C Finley; Rosa-ana Risques; Wen-Tang Shen; Katherine A Gollahon; Alexander H Moskovitz; Sergei Gryaznov; Calvin B Harley; Peter S Rabinovitch Journal: Cytometry A Date: 2004-04 Impact factor: 4.355
Authors: Kellie E Cunningham; Garret Vincent; Chhinder P Sodhi; Elizabeth A Novak; Sarangarajan Ranganathan; Charlotte E Egan; Donna Beer Stolz; Matthew B Rogers; Brian Firek; Michael J Morowitz; George K Gittes; Brian S Zuckerbraun; David J Hackam; Kevin P Mollen Journal: J Biol Chem Date: 2016-03-11 Impact factor: 5.157
Authors: Kathryn T Baker; Daniela Nachmanson; Shilpa Kumar; Mary J Emond; Cigdem Ussakli; Teresa A Brentnall; Scott R Kennedy; Rosa Ana Risques Journal: Mol Cancer Res Date: 2018-11-16 Impact factor: 5.852